Posts

Eisai Co. Ltd. initiated Phase 3 clinical trials of the Alzheimer’s treatment BAN2401 one day after the Japanese drugmaker and U.S. partner Biogen Inc. scrapped studies for the Alzheimer’s drug aducanumab.

There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.

WASHINGTON, July 19, 2015 /PRNewswire-USNewswire/ — Promising early results of new drugs that target common components of several brain diseases that cause dementia – including Alzheimer’s disease, Parkinson’s disease, and Lewy Body dementia – were reported today at the Alzheimer’s Association International Conference® 2015 (AAIC® 2015) in Washington, D.C. These diseases cause a range of […]